中重度急性肾损伤出院时使用RAAS抑制剂与再发AKI及死亡率的关联
该回顾性队列研究纳入96,983例存活的中重度(II或III期)急性肾损伤退伍军人,其中40%出院时使用RAAS抑制剂。倾向评分加权Cox模型显示,停用RAAS抑制剂者再发AKI风险无差异,但死亡率显著升高(HR 1.33, 95%CI 1.26-1.41)。
要点
- 中重度AKI存活者出院时使用RAASi与再发AKI风险无显著差异。
- 停用RAASi者死亡率显著高于继续使用者(HR 1.33, 95%CI 1.26-1.41)。
- 有强适应症者重新启用RAASi可能获益,但需平衡再发AKI风险并监测。
核心结论
- 中重度AKI存活者使用RAASi与再发AKI风险无显著差异,但与改善生存相关。
研究设计与样本
- 回顾性队列研究,纳入96,983例存活的中重度(II或III期)AKI退伍军人,采用倾向评分加权Cox比例风险模型。
主要发现
- 40%患者出院时使用RAASi。
- 停用RAASi者与继续使用者相比,再发AKI风险无差异,但死亡率风险显著更高(HR 1.33, 95%CI 1.26-1.41)。
- 非使用者新启用RAASi与持续使用者相比,再发AKI风险无差异。
- 亚组分析(糖尿病、CKD、心衰、恶性肿瘤)结果相似,仅CKD中停用RAASi者再发AKI风险轻度降低。
临床怎么用
- 对有强适应症的中重度AKI存活者,应考虑重新启用或启动RAASi。
- 启用RAASi需个体化平衡再发AKI风险,并进行充分监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recurrent episodes of acute kidney injury (AKI) are common among AKI survivors. Renin-angiotensin aldosterone inhibitors (RAASi) are often indicated for these patients but may increase the risk for recurrent AKI. Here, we examined whether RAASi associates with a higher risk for recurrent AKI and mortality among survivors of moderate to severe AKI in a retrospective cohort of Veterans who survived Stage II or III AKI. The primary exposure was RAASi at hospital discharge and the primary endpoint was recurrent AKI within 12 months. Cox proportional hazards models were fit on a propensity score-weighted cohort to compare time to recurrent AKI and mortality by RAASi exposure. Among 96,983 patients, 40% were on RAASi at discharge. Compared to patients who continued RAASi use, those discontinuing use experienced no difference in risk for recurrent AKI but had a significantly higher risk of mortality [hazard ratio 1.33 (95% confidence interval1.26-1.41)]. No differences in recurrent AKI risk was observed for non-users started or not on RAASi compared to prevalent users who continued RAASi. Subgroup analyses among those with diabetes, chronic kidney disease, heart failure, and malignancy were similar with exception of a modest reduction in recurrent AKI risk among RAASi discontinuers with chronic kidney disease. Thus, RAASi use among survivors of moderate to severe AKI was associated with little to no difference in risk for recurrent AKI but was associated with improved survival. Reinitiating or starting RAASi among patients with strong indications is warranted but should be balanced with individual overall risk for recurrent AKI and with adequate monitoring.
引用
- Siew ED, Parr SK, Abdel-Kader K, et al. Renin-angiotensin aldosterone inhibitor use at hospital discharge among patients with moderate to severe acute kidney injury and its association with recurrent acute kidney injury and mortality. Kidney Int. 2020. PMID: 32916177. doi:10.1016/j.kint.2020.08.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。